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Update on an Immortalized Human Microvascular Endothelial Cell 
The perceived importance of endothelial cells in human biology 
and medicine has increased dramatically in the last decade. These 
cells have critical functions in a wide variety of biologic processes 
including leukocyte trafficking, wound healing, inflammation, and 
tumor metastasis, and they have attracted the attention of biotech-
nology and pharmaceutical firms. They are attractive targets for 
gene-therapy strategies, and numerous attempts are underway to 
regulate the expression of cell adhesion molecules on endothelial 
cells. Amidst this flurry of activity it has been widely assumed that 
all human endothelial cells are alike, but recent information indi-
cates clearly that microvascular endothelial cells differ in several 
biologically significant ways from large-vessel endothelial cells. Al-
though over 13,000 articles have been written about endothelial 
cells in the last six years, only 26 have focused on microvascular 
endothelial cells, despite the fact that many or most physiologic and 
pathologic events that involve endothelial cells take place at the 
level of the microvasculature. In fact, many biologists would like to 
study the human microvasculature in detail, but the isolation of 
human microvascular endothelial cells is difficult, tedious, and ex-
pensive. In this issue, Xu et al (p . 833) provide an update on the 
characterization of the first immortalized human microvascular en-
dothelial cell line, HMEC-1, originally described in the December 
1992 issue of the JOHrnal by Ades et al U In vest Dermato199:683 - 690, 
1992). These immortalized cells are inexpensive to culture and pro-
vide a limitless supply of cells. Most important, they retain almost 
all the characteristics of endothelial cells. In this issue, Xu et al flesh 
ou.t the phenotypic and functional profile of these cells. Although 
tl1lS celllllle does not perfectly recapitulate all the characteristics of 
micro~ascular endot~elial cells from skin, it should prove to be very 
useful III understandlllg the role of the microvascular endothelium 
in human diseases. 
Interleukin 7 - ANew Alternative in the Immunotherapy of Melanoma? 
Immunotherapy with interleukin 2 (IL-2), which induces lympho-
cyte-activated killer (LAK) cells, has achieved some impressive re-
gressions in patients with advanced melanoma who have not re-
sponded to conventional therapy, but the toxicity ofIL-2, including 
pulmonary congestion, hypotension, and the capillary leakage syn-
drome, can be severe. IL-7, a recently described pre-B-cell growth 
fac tor that is involved in development ofT lymphocytes, may hold 
some promise. In this issue, Schadendorf and co-workers (p. 838) 
compared the ability ofIL-7 and IL-2 to induce LAK activity against 
human melanoma cells, keratinocytes, or endothelial cells. IL-7-
induced LAK cells lysed human melanoma cells ill vitro but were not 
as efficient as IL-2 - generated LAK cells. Keratinocytes and endo-
thelial cells, however, were not killed by IL-7 - generated LAK cells 
alone, indicating that IL-7 has more specificity for melanoma cells, 
but were killed after addition of IL-2-induced LAK cells. The 
action of IL-2 on keratinocytes and endothelial cells, which may in 
turn be caused by TNF-Cl' produced by administration ofIL-2, may 
produce undesirable toxic side effects during IL-2 immunotherapy. 
TNF-Cl' levels induced by administration of IL-7, however, are 
much lower than those produced by IL-2. IL-7 may be useful be-
cause it is more specific for melanoma cells, even though it is less 
effective against melanoma cells than IL-2. If IL-7 -induced LAK 
activity alone is too weak for immunotherapy, the more discrimina-
tive killing spectrum of IL-7 - generated LAK cells compared to 
IL-2 - generated cells may be useful in the treatment of melanoma. 
Furthermore, combining the two cytokines might lead to reduced 
toxic side effects as well as to higher LAK activity against melanoma 
cells. 
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Interleukin-4 - Chemotactic for Eosinophils in Atopic Dermatitis 
Skin of patients with atopic dermatitis is infiltrated with T cells, and 
allergen-specific T cells have been cloned from lesional skin U 
Invest Dermatol97:389 - 394, 1991). In vitro, allergen-specific T cells 
are able to produce both IL-4 and IL-S and are therefore considered 
to be of the Th2 phenotype. These findings suggest that T cells may 
be capable of releasing IL-4 in atopic skin. Although eosinophils are 
uncommon in atopic skin, deposits of eosinophil granular compo-
nents are present, indicating that activated eosinophils have been 
present in the skin and have degranulated. No influx of neutrophils 
has been observed, however, suggesting a selective infiltration of 
eosinophils. This is usually explained by the effect ofIL-4 on endo-
thel ial cells, because IL-4 induces the expression of endothelial cell 
adhesion molecules specific for eosinophils but not for neutrophils. 
Because IL-4 plays a predominant role in allergic inflammation and 
has been shown to be chemotactic for fibroblasts, Dubois et al (p. 
843) investigated the effects of IL-4 on eosinophils. These investi-
gators found that IL-4 also has the capacity to act directly on eosino-
phils, inducing a chemotactic response. In contrast to eosinophils 
from controls, which did not respond, eosinophils from patients 
with atopic dermatitis migrated toward a source of IL-4 . This sug-
gests that eosinophils infiltrating the tissue can be recruited to sites 
where high levels of IL-4 are present and may be further activated 
by IL-4 to release their toxic granular components. These experi-
ments raise the possibility that interference with the secretion or 
action of IL-4 might decrease the toxic potential of infiltrating 
eosinophils in the tissue and thereby be helpful in atopic dermatitis. 
A Mouse Model for Alopecia Areata 
Aging C3H/HeJ mice develop focal, round areas of balding dorsal 
skin and diffuse hair loss on ventral skin that closely resembles the 
human disorder alopecia areata. Because C3H/HeJ mice are in gen-
eral prone to developing autoimmune diseases, Sundberg's labora-
tory at the Jackson Laboratories in Bar Harbor, Maine, and King at 
Vanderbilt sought additional evidence that the condition resembled 
alopecia areata. Biopsies showed nonscarring alopecia limited to 
anagen-stage follicles and surrounded by mononuclear cells, similar 
to the human disorder. In the mouse, normal adult hair follicles 
remain in telogen for long periods, unlike human hair follicles, 
which are sht::d in a random, mosaic pattern and grow for much 
longer periods. New hair growth is initiated beginning at the head 
and progressively moves like a wave toward the tail. In mice with 
alopecia, only the anagen follicles in this wave of new hair growth 
are affected. Lymphocytes, primarily CD8+ and to a less extent 
CD4+ cells, infiltrate in and around the anagen follicles in affected 
C3H/HeJ mice, and the inflammation is associated with disruption 
of the inner and outer root sheath of the affected follicle. This 
produces a defective hair shaft that breaks off when it exits the 
follicle, giving rise to exclamation point hairs and other hair shaft 
abnormalities. These findings, described in this issue (p. 847), sup-
port the concept that the mouse model for alopecia areata is a.n 
autoimmune disease and that the immune cells around the hall 
follicles are responsible for inducing or maintaining abnormal hair 
growth. Also, hair regrows in response to intralesional steroid injec-
tions, a treatment commonly used for people with alopecia areata, 
supporting the similarity to alopecia areata and suggesting that the 
model can be used to develop and test new treatments for alopecia 
areata. Preliminary genetic studies suggest that the phenotype in 
C3H/HeJ mice is caused by several abnormal genes that have to 
work together (i.e. , it is a polygenic trait). This mouse model pro-
vides a system in which investigations can be pursued in detail under 
strictly controlled circumstances, something that cannot be done 
with human volunteers. 
IGF-I: An Important Regulator of Hair Follicle Growth and the Hair Growth Cycle In Vitro 
In mammals hair growth is cyclical. Three distinct stages can be 
identified: an active growth state, anagen, during which hair 
growth occurs; an intermediate, regressive, catagen stage; and a 
resting state, telogen. The factors that regulate hair follicle growth 
and the hair-growth cycle are poorly understood, but it is likely that 
known growth factors playa role, and this possibility is under inves-
tigation in several laboratories. The insulin-like growth factors 
(IGF-I and II) are small diffusable factors similar to insulin in both 
structure and function . IGF-I has been shown to act as a mitogen for 
keratinocytes at physiologic concentrations, about 10-9 M, whereas 
insulin stimulates proliferation only at unphysiologically high con-
centrations on the order of 10- 6 M. In this issue, Philpott et al (p. 
857) have studied the effects ofIGF-l on intact hair follicles in vitro 
using a technique devised in Philpott's laboratory. They report that 
insulin at supraphysiologic concentrations (10 Ilg per ml, or about 
10- 6 M) can support human hair follicle growth and that in the 
absence of insulin these cultured hair follicles show premature entry 
into catagen. IGF-1, however, in the absence of insulin, not only 
stimulated hair follicles growth to the same extent as insulin but also 
prevented the premature entry into catagen; both effects were found 
at physiologic concentrations ofIFG-1 (10 ng per ml, or about 10- 9 
M). IGF-II stimulated hair follicle growth in the absence of insulin 
and prevented premature entry into catagen, although not to the 
same extent as IGF-l and only at higher a higher concentration (100 
ng per ml) . These studies show that IGF-1 is a potent growth factor 
for hair follicles and raise the possibility that IGF-l may also playa 
major role in regulation of the hair-growth cycle. 
